Purchase Order 140D0426P0139
Award Date 6/1/26
Potential Completion Date 8/24/26
Potential Value $111K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Other Statutory Authority
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Cancer Institute (NCI) awarded a firm fixed-price purchase order to Illumina, Inc., a for-profit manufacturer of genomics sequencing systems and reagents, for the procurement of an Illumina NextSeq 550 sequencing system. The $266,475 award was made on May 24, 2019 with an August 22, 2019 completion date. This purchase will complement the NCI's existing Illumina NextSeq 500 and MiSeq instruments used by...
- The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a firm-fixed-price purchase order to Illumina, Inc., a for-profit manufacturer of sequencing and genomic analysis instruments and reagents, to provide an Illumina NextSeq 2000 genetic analysis sequencer. The sequencer will be used to acquire whole genome, whole exome, and whole transcriptome data to support the National Cancer Institute's efforts to develop novel cancer...
- <p>The National Cancer Institute issued a delivery order to Illumina, Inc. on June 26, 2018, with a ceiling value of $13,043.75 and an ultimate completion date of July 26, 2018.</p> <p>Place of performance is Bethesda, MD 20892. The order is priced on a firm fixed-price basis with no set-aside designation. The delivery order procures genetic sequencing equipment, reagents, consumables, or related bioinformatics services from Illumina's portfolio of genomic analysis technologies.</p>
- <p>The National Cancer Institute issued a delivery order to Illumina, Inc. on July 26, 2017, with a ceiling value of $22,188.47 for genetic sequencing equipment and consumables, with ultimate completion by August 28, 2017.</p> <p>Place of performance is Bethesda, MD. The order is firm fixed price with no set-aside designation. Illumina specializes in DNA and RNA sequencing instruments, reagents, and bioinformatics software supporting genomic research across federal agencies.</p>
- This is a $15,388.08 firm fixed-price purchase order awarded by the National Cancer Institute (NCI), a civilian federal agency, to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis products. The contract is for a service agreement for a MiSeq M05802 sequencing system, with a completion date of December 7, 2025. Illumina has previously received prime contracts and subcontracts from various federal agencies, including the NIH, CDC, USDA, and VA, to provide sequencing...
- <p>The National Cancer Institute issued a delivery order to Illumina, Inc. on July 23, 2015, with a ceiling value of $24,772.41 for genomic sequencing equipment and reagents.</p> <p>Place of performance is Baltimore, Maryland. The order was firm fixed price with no set-aside. Ultimate completion date was April 12, 2020.</p>
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $238,017.50 firm fixed price purchase order to Illumina, Inc. for the acquisition of an Illumina NextSeq 2000 sequencing system. The award did not include any set-aside designation. The sequencing system will support the National Cancer Institute's Surgery Branch in developing novel immunotherapies for the treatment of various cancers, including melanoma, gastrointestinal, lung, and...
- This is a $16,198 firm fixed price purchase order awarded by the National Cancer Institute to Illumina, Inc. for a service agreement to provide their MiSeq next-generation sequencing instrument. The contract has no set-aside designation and runs through July 31, 2025. Illumina is a manufacturer of genomic sequencing and analysis instruments and has previously been awarded prime contracts and subcontracts by the National Institutes of Health (NIH), Centers for Disease Control and Prevention...
- <p>The National Cancer Institute issued a delivery order to Illumina, Inc. on September 7, 2017, with a ceiling value of $6,700.18.</p> <p>Place of performance is Bethesda, MD 20892. The order has a firm fixed-price structure and an ultimate completion date of October 8, 2017. The delivery order calls for genetic sequencing equipment, reagents, consumables, or bioinformatics software consistent with Illumina's portfolio of DNA and RNA sequencing instruments and analytical tools.</p>
- <p>The National Cancer Institute issued a delivery order to Illumina, Inc. on October 23, 2017, with a ceiling value of $6,892.55. Place of performance is Bethesda, MD. The order is for genetic sequencing equipment, reagents, or consumables consistent with Illumina's portfolio of DNA and RNA sequencing instruments and bioinformatics software supporting genomic research. The ultimate completion date is November 19, 2017. The order is priced as firm fixed price with no set-aside designation.</p>